Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:34:16.709Z.
Calculation as of: 2026-10-06T17:34:16.709Z.
Quote observation: 2026-10-06T17:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a19952d2edecd783a1a7aa32ab0a3489a492a6ad3733958836c0f0d47bc8061
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Spruce Biosciences, Inc.
Market Cap
$119.50M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $119.50M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.81M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Cibus, Inc. (CBUS)vs › | $120.60M | N/A |
| Seer, Inc. (SEER)vs › | $121.05M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.68M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.49M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.64M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $115.05M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
